Oryzon Genomics S.A. (0RDB.L)

EUR 1.6

(-4.88%)

Total Liabilities Summary of Oryzon Genomics S.A.

  • Oryzon Genomics S.A.'s latest annual total liabilities in 2023 was 27.73 Million USD , down -16.78% from previous year.
  • Oryzon Genomics S.A.'s latest quarterly total liabilities in 2024 Q2 was 25.87 Million USD , down 0.0% from previous quarter.
  • Oryzon Genomics S.A. reported annual total liabilities of 33.33 Million USD in 2022, up 21.4% from previous year.
  • Oryzon Genomics S.A. reported annual total liabilities of 27.45 Million USD in 2021, up 23.65% from previous year.
  • Oryzon Genomics S.A. reported quarterly total liabilities of 28.48 Million USD for 2023 Q2, down 0.0% from previous quarter.
  • Oryzon Genomics S.A. reported quarterly total liabilities of 27.73 Million USD for 2023 Q4, down 0.0% from previous quarter.

Annual Total Liabilities Chart of Oryzon Genomics S.A. (2023 - 2012)

Historical Annual Total Liabilities of Oryzon Genomics S.A. (2023 - 2012)

Year Total Liabilities Total Liabilities Growth
2023 27.73 Million USD -16.78%
2022 33.33 Million USD 21.4%
2021 27.45 Million USD 23.65%
2020 22.2 Million USD 4.37%
2019 21.27 Million USD -16.82%
2018 25.57 Million USD -19.89%
2017 31.92 Million USD 12.29%
2016 28.43 Million USD 99.28%
2015 14.26 Million USD -3.1%
2014 14.72 Million USD -23.82%
2013 19.32 Million USD 56.48%
2012 12.35 Million USD 0.0%

Peer Total Liabilities Comparison of Oryzon Genomics S.A.

Name Total Liabilities Total Liabilities Difference
Boiron SA 198.7 Million EUR 86.04%
Laboratorios Farmaceuticos Rovi, S.A. 256.39 Million EUR 89.181%
Vetoquinol SA 165.12 Million EUR 83.201%
Valneva SE 341.14 Million EUR 91.869%
AB Science S.A. 46.5 Million EUR 40.358%
Nanobiotix S.A. 95.74 Million EUR 71.027%
PHAXIAM Therapeutics S.A. 25.69 Million EUR -7.953%
Vivoryon Therapeutics N.V. 4.54 Million EUR -510.039%
BioSenic S.A. 32.26 Million EUR 14.027%
ABIVAX Société Anonyme 131.05 Million EUR 78.834%
Formycon AG 387.61 Million EUR 92.844%